| Page 1681 | Kisaco Research
 

Guy Paillet

Co-Founder
General Vision

Guy is the inventor of the ZISC (Zero Instruction Set Computer), a silicon neural network chip back in 1993. He brings a long experience in hard-wired artificial vision systems and parallel pattern recognition architecture to the company. He is an “out-of-the-box” thinker and can solve complex problems related to sensing (especially vision) and artificial intelligence with elegant, yet practical solutions. Guy talent has served in several companies including Data Sud Systems (DSS), IBM, EuroPixels and General Vision Inc.

Guy Paillet

Co-Founder
General Vision

Guy Paillet

Co-Founder
General Vision

Guy is the inventor of the ZISC (Zero Instruction Set Computer), a silicon neural network chip back in 1993. He brings a long experience in hard-wired artificial vision systems and parallel pattern recognition architecture to the company. He is an “out-of-the-box” thinker and can solve complex problems related to sensing (especially vision) and artificial intelligence with elegant, yet practical solutions. Guy talent has served in several companies including Data Sud Systems (DSS), IBM, EuroPixels and General Vision Inc.

 

Bruno Maisonnieer

CEO
AnotherBrain

Bruno Maisonnieer

CEO
AnotherBrain

Bruno Maisonnieer

CEO
AnotherBrain
 
OCTS 2020
7-9 Jul 2020
VIRTUAL SUMMIT | EDT Timezone
Onco Cell Therapy Summit (OCTS), formerly the CAR-T Congress, is an event that brings industry together to share novel research, manufacturing techniques and regulatory best practice. Each session of OCTS 2020 is dedicated to translating your novel data assets & IP into commercially viable oncological therapies.OCTS is a 4-track event and whilst bringing together the key decision makers for CAR-T therapies, this year’s event will have an added focus on the ground breaking science that is driving the surge of interest in harnessing alternative cell therapies in cancer treatments.With 2 of our tracks comprised of research on CAR-T and alternative cell therapies, the other pillar in rolling out these therapies is increasing the affordability of the treatments. The other two tracks will delve into best practice in commercialization and manufacturing of immuno-oncological cell therapies.Each day of the summit will conclude in plenary room panels that spin out into bespoke roundtable discussions to break down the key challenges in major topics to R&D, manufacturing and commercialization.
 

Jennifer Malin

Senior Medical Director
Oncology & Genetics, UHC

Jennifer Malin

Senior Medical Director
Oncology & Genetics, UHC

Jennifer Malin

Senior Medical Director
Oncology & Genetics, UHC
 

Marcelo Pasquini

Senior Scientific Director of Clinical Trials Support
CIBMTR

Marcelo Pasquini

Senior Scientific Director of Clinical Trials Support
CIBMTR

Marcelo Pasquini

Senior Scientific Director of Clinical Trials Support
CIBMTR
 

Caron Jacobson

Medical Director
Dana-Faber Cancer Institute

Caron Jacobson

Medical Director
Dana-Faber Cancer Institute

Caron Jacobson

Medical Director
Dana-Faber Cancer Institute
 

Roman Yelensky

EVP & CTO
Gritstone Oncology

Roman Yelensky

EVP & CTO
Gritstone Oncology

Roman Yelensky

EVP & CTO
Gritstone Oncology
 

Alex Franzusoff

CEO
PACT Pharma

Alex Franzusoff

CEO
PACT Pharma

Alex Franzusoff

CEO
PACT Pharma
 

James Trager

Chief Scientific Officer
Nkarta

James Trager

Chief Scientific Officer
Nkarta

James Trager

Chief Scientific Officer
Nkarta
 

Jeffrey Miller

Professor
University of Minnesota

Jeffrey Miller

Professor
University of Minnesota

Jeffrey Miller

Professor
University of Minnesota